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Abstract
Background In this study, we investigated the effects
of 2-(2-fluorophenyl)-6,7-methylenedioxyquinolin-4-one
(CHM-1) on cell viability, cell cycle arrest and apoptosis in
CT-26 murine colorectal adenocarcinoma cells.
Methods For determining cell viability, the MTT assay
was used. CHM-1 promoted G2/M arrest by PI staining and
flow cytometric analysis. Apoptotic cells were evaluated by
DAPI staining. We used CDK1 kinase assay, Western blot
analysis and caspase activity assays for examining the
CDK1 activity and proteins correlated with apoptosis and
cell cycle arrest. The in vivo anti-tumor effects of CHM-1-P
were evaluated in BALB/c mice inoculated with CT-26
cells orthotopic model.
Results CHM-1 induced CT-26 cell viability inhibition
and morphologic changes in a dose-dependent and time-
dependent manner and the approximate IC50 was
742.36 nM. CHM-1 induced significant G2/M arrest and
apoptosis in CT-26 cells. CHM-1 inhibited the CDK1
activity and decreased CDK1, Cyclin A, Cyclin B protein
levels. CHM-1 induced apoptosis in CT-26 cells and pro-
moted increasing of cytosolic cytochrome c, AIF, Bax, BAD,
cleavage of pro-caspase-9, and -3. The significant reduction
of caspase-9 and -3 activity and increasing the viable CT-26
cells after pretreated with caspase-9 and -3 inhibitor indi-
cated that CHM-1-induced apoptosis was mainly mediated a
mitochondria-dependent pathway. CHM-1-P improved mice
survival rate, and enlargement of the spleen and liver
metastasis were significantly reduced in groups treated with
either 10 mg/kg and 30 mg/kg of CHM-1-P and 5-FU in
comparison to these of CT-26/BALB/c mice.
Conclusions Taken together, CHM-1 acted against colo-
rectal adenocarcinoma cells in vitro via G2/M arrest and
apoptosis, and CHM-1-P inhibited tumor growth in vivo.
Keywords CHM-1 and CHM-1-P  CT-26 colorectal
adenocarcinoma cells  Apoptosis  G2/M arrest 
Orthotopic model
Introduction
Colorectal cancer is one of the major causes of deaths in
the world, and it is the third leading cause of cancer death
in Taiwan. According to the People Health Bureau of
Taiwan, there are about 37.4 new cases per 100,000 people
per year [1]. Colorectal cancer is a multi-step process
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involving progressive disruption of intestinal epithelial
cells proliferation [2]. The 5-fluorouracil (5-FU) is one of
the used chemotherapeutic agents in first-line therapy for
colorectal cancer, but serious side effects such as nausea,
fatigue, and a decline in the number of blood cells, and
limits its clinical usefulness [3, 4]. New compounds that
are not detrimental to normal cells and exert cytotoxic
effects only on colorectal cancer cells are considered to be
the most chemotherapeutic effective. The progression of
the cell cycle has been intensively investigated, particularly
CDK1/Cyclin B complex’s important role in the regulation
of G2/M phase [5, 6]. Anti-mitotic agents affecting
microtubule assembly or disassembly have been shown to
interfere with the progression of the cell cycle, and some of
them have shown significantly clinical anti-cancer effects
[7, 8]. Numerous evidences have shown that induction of
cell death in tumor cells is through cell cycle arrest and
apoptosis [9, 10].
Selectively inducing apoptosis in colorectal cancer cells
has been increasingly recognized as a promising therapeutic
approach for colorectal cancer. Recently, we have designed
and synthesized a series 2-phenyl-4-quinolone series com-
pounds as novel anti-mitotic agents, CHM-1 (2-(2-fluoro-
phenyl)-6,7-methylenedioxyquinolin-4-one, as shown in
Fig. 1a) is the potential compound for anti-cancer activities.
CHM-1 significantly inhibited tubulin polymerization and
showed cytotoxic effect on many human tumor cell lines
(SK-Hep-1, HA22T, Hep3B, HepG2 and U2-OS cells) [11,
12]. We also have designed and synthesized CHM-1-P
(2-(2-fluorophenyl)-6,7-methylenedioxyquinolin-4-yl dihy-
drogen phosphate, as shown in Fig. 1a), and it was quickly
converted into its active parent compound CHM-1 in vivo by
pharmacokinetic analysis. However, neither the cytotoxic
effects of CHM-1 and CHM-1-P on colorectal cancer cells
nor the molecular mechanisms underlying its anti-cancer
activity have been revealed. Therefore, in this study, we
investigated the molecular mechanisms of its anti-cancer




4-one) and CHM-1-P (2-(2-fluorophenyl)-6,7-methylene-
dioxyquinolin-4-yl dihydrogen phosphate; Fig. 1) were
synthesized and obtained from Dr. Sheng-Chu Kuo in
Graduate Institute of Pharmaceutical Chemistry, College of
Pharmacy, China Medical University. Potassium phos-
phates, dimethyl sulfoxide (DMSO), Propidium iodide (PI),
Triton X-100, Tris–HCl, Ribonuclease-A were purchased
from Sigma Chemical Co. (St. Louis, MO, USA). Caspase-
9 inhibitor (Z-LEHD-FMK), caspase-3 inhibitor (Z-
DEVD-FMK) (R&D, USA) were dissolved in DMSO and
diluted in cell culture medium before use.
Cell culture
CT-26 colorectal adenocarcinoma cells, N-nitroso-N-
methyl urethane-induced mouse colon carcinoma cells of
BALB/c origin, were purchased from the American Type
Culture Collection (ATCC, Manassas, VA, USA). Cells
were cultured in RPMI-1640 medium (GIBCO, Grand
Island, NY, USA) supplemented with 10% heat-inactivated
fetal calf serum (Hyclone, Logan, UT, USA) at 37C in a
humidified 5% CO2 and 95% air at 1 atm incubator. Full
grown monolayer cultures were trypsinized (0.25% trypsin-
EDTA), harvested and passaged several times for expansion
[13].
Determinations of cell viability by MTT assay
The CT-26 cells were seeded onto 96-well cell culture
plates at 2.5 9 104 cells/well then incubated with 0, 250,
500, 750 and 1000 nM of CHM-1 for 24, 48 and 72 h.
Then the cells were treated by the addition of MTT dye to
each well. After an additional 4 h incubation, the growth
medium was removed and the formazan crystals, formed
by oxidation of the MTT dye, were dissolved with 0.04 N
HCl in isopropanol. The absorbance was measured at
570 nm and the cell survival ratio was expressed as a
percentage of the control [14].
Determinations of cell cycle and apoptosis
by PI staining
The CT-26 cells were seeded onto 24-well cell culture
plates at 2.5 9 105 cells/well then incubated with 750 nM
of CHM-1 for 0, 12, 24 and 48 h. The cells were harvested
and washed by centrifugation. For cell cycle and apoptosis
determination, cells were fixed gently by putting 70%




2-(2-fluorophenyl)-6,7-methylenedioxyquinolin-4-yl dihydrogen phosphate (CHM-1-P) 
Fig. 1 The structure of CHM-1 (a) and CHM-1-P (b)
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containing 40 lg/ml PI and 0.1 mg/ml RNase and 0.1%
Triton X-100 in dark room for 30 min. The cell cycle and
apoptotic nuclei were determined by flow cytometry
(FACS CaliburTM, Becton Dickinson, Franklin Lakes, NJ,
USA) as described previously [15].
DAPI staining
The CT-26 cells were seeded onto 6-well cell culture plates
at 2.5 9 105 cells/well then incubated with 750 nM of
CHM-1 for 0 and 24 h. After incubation for the indicated
periods of time, the cells were fixed gently by 70% ethanol,
then the cells were stained with DAPI (4,6-diamidino-2-
phenylindole dihydrochloride), then photographed using a
fluorescence microscope as described previously [16].
CDK1 kinase assay
CDK1 kinase activity was analyzed according to the pro-
tocol of Medical & Biological Laboratories CDK1 kinase
assay kit (MBL, Nagoya, Japan). About 1 9 106 cells were
suspended in a buffer containing, in a final volume of
0.2 ml, 50 mM Tris–HC1, pH 7.5, 1 mM phenylmethyl-
sulfonyl fluoride, 50 pg/ml leupeptin, 10 mM 2-mercap-
toethanol, 1 mM MgCl, 2 mM EGTA, 0.5 mM
dithiothreitol, 0.01% Brij35, 25 mM b-glycerophosphate,
and 0.5 M NaCl. Cell suspensions were sonicated and
centrifuged at 100,0009g for 30 min. To determine the
CDK1 kinase assay condition using MV Peptide, and
determined by measuring OD 492 as described previously
[17].
Caspase activity assay
The CT-26 cells were seeded onto six-well cell culture
plates at 2.5 9 106 cells/well then incubated with 750 nM
of CHM-1 or caspase-3 inhibitor (Z-DEVD-FMK), cas-
pase-9 inhibitor (Z-LEHD-FMK) for 1 h prior to treatment
with CHM-1 for 6, 12, 18 and 24 h. Cytosolic fraction
proteins were prepared and determined as described pre-
vious [17, 18]. About 50 lg of cytosol proteins were
incubated with caspase-3 and -9 specific substrates
[Ac-DEVD-pNA and Ac-IETD-pNA (R&D System)] for
1 h at 37C. The caspase activity was determined by
measuring OD 405 as described previously [17, 18].
Western blotting
The CT-26 cells were seeded onto 10-cm dish at an initial
concentration of 1.0 9 107 cells and incubated with
750 nM of CHM-1 for 6, 12 and 24 h. Cytosolic fraction
and total protein were prepared and determined as descri-
bed previous [17, 18]. Equal amount of proteins (30 lg)
were separated by SDS-PAGE and transferred onto PVDF
membrane. Blots were blocked in PBST buffer (0.05%
Triton X-100 in PBS) buffer containing 5% non-fat milk
for 1 h, the membrane was incubated overnight at 4C with
specific primary antibodies (Cyclin A, Cyclin B, CDK1,
Cytochrome c, Pro-caspase-9, Pro-caspase-3 AIF, Bax,
BAD, Bcl-2, Bcl-xL and Actin). The membrane was
washed with PBST buffer and incubated with horseradish
peroxidase (HRP) conjugated secondary antibodies. The
specific protein was detected by using enhanced chemilu-
minescence kits (Amersham ECL Kits) [15–17].
In vivo anti-colorectal cancer activity in CT-26
orthotopic model
About 80 male BALB/c mice of 22–28 g in weight at the
age of 8 weeks were obtained from Laboratory Animal
Center, College of Medicine, National Taiwan University
(Taipei, Taiwan). The BALB/c mice were maintained at
the Animal Center of China Medical University for
2 weeks under animal guidelines before the grouping and
experiments. The BLAB/c mice were divided into four
groups and each group contained twenty animals. Group I
was injected i.p. with 1.0 9 106/100 ll of CT-26 cells as a
control. Group II was injected with CT-26 cells and treated
with (10 mg/kg, oral) CHM-1-P in PBS. Group III was
injected with CT-26 cells and treated with (30 mg/kg, oral)
CHM-1-P in PBS. Group IV was injected with CT-26 cells
and treated with (30 mg/kg, oral) 5-fluorouracil (5-FU,
i.p.). Anti-colorectal cancer activity was assessed as the
survival time (each group contained ten animals) in the
treatment and un-treated group. Furthermore, the CHM-1
and 5-FU groups (each group also contained ten animals)
were treated on 35 days then the animals were weighed and
killed. Anti-tumor activity was assessed as the ratio of
median survival time (MST) in the treatment group (T) to
MST in the control group (C), and the results are shown as
T/C: life span T/C (%) = (MST of drug-treated group/
MST of control group) 9 100. Long-term survivors were
recorded until each animal died. The colon, liver and
spleen samples were isolated and weighed individually for
histopathology. The total tumor volume in each animal was
estimated according to the formula: total tumor volume
(mm3) = L 9 W2/2, where L is the length and W is the
width [19].
Statistical analysis
In vitro study, Student’s t test was used to analyze differ-
ences between CHM-1-treated and control groups.
*p \ 0.05, **p \ 0.01, ***p \ 0.001. In vivo study, mice
body and spleen weight results were expressed as
mean ± SD and the difference between the groups were
J Gastroenterol (2009) 44:1055–1063 1057
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tested by one way ANOVA. Significant differences
between values for CT-26/BALB/c mice and various
treatment are shown ***p \ 0.001.
Results
Next, we examine the effects of CHM-1 on cell viability
and morphology of CT-26 cells. CT-26 cells were treated
with CHM-1 (Fig. 1a) at 250, 500, 750 and 1000 nM. The
cell viability was determined by MTT method at 24, 48 and
72 h later. As shown in Fig. 2a, CHM-1 reduces CT-26 cell
viability in a dose- and time-dependent manner. The
approximate IC50 was 742.36 nM. Apoptotic morphologi-
cal examinations in Fig. 2b by DAPI staining and the result
show that CHM-1 induced DNA condensation and apop-
tosis in the CT-26 cells.
CHM-1 induced G2/M arrest and apoptosis in CT-26
cells. We investigated whether CHM-1 could induce cell
cycle arrest and apoptosis in CT-26 cells. Cells were
treated with 750 nM of CHM-1 for 12, 24 and 48 h then
were analyzed cell cycle distribution by PI staining and
flow cytometry. As shown in Fig. 3a, CHM-1 induced
a time-dependent accumulation of G2/M population in
CT-26 cells (13.82% G2/M at 0 h; 44.63% G2/M at 12 h;
53.26% G2/M at 24 h; 66.84% G2/M at 48 h), and then the
cells underwent apoptosis (1.02% Sub-G1 at 0 h; 18.68%
Sub-G1 at 12 h; 45.68% Sub-G1 at 24 h; 61.05% Sub-G1
at 48 h). To expose the mechanisms of CHM-1 induced
G2/M arrest, we investigated the protein expressions of
CDK1, Cyclin A, Cyclin B by Western blotting, and the
CDK1 activity determination. After exposure to 750 nM of
CHM-1, CT-26 showed a decrease in the protein levels of
CDK1, Cyclin A and Cyclin B that were examined by
Western blotting (Fig. 3b). CDK1 kinase assays on CHM-1
treated CT-26 cells showed a significant decrease in the
activity of CDK1 at 12 and 24 h after CHM-1 treatment
(Fig. 3c).
Fig. 2 Effects of CHM-1 on the
percentage of CT-26 cell
viability (a) and DNA
condensation by DAPI staining
(b). Cells were cultured with 0,
250, 500 and 1000 nM of
CHM-1 for 24, 48 and 72 h. For
percentages of viable cells were
detected by MTT assay
described in ‘‘Materials and
methods’’. Each point is a
mean ± SD as of three
experiments. For DAPI staining,
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Effects of CHM-1 on the levels of apoptosis associated
proteins in CT-26 cells. To examine whether the mito-
chondrial-mediated apoptotic pathway was involved in
CHM-1-induced apoptosis, we examined the expression
levels of these Bcl-2 family proteins (Bax, BAD, Bcl-2 and
Bcl-xL) and cytosolic cytochrome c, pro-caspase-9, pro-
caspase-3 and AIF. As shown in Fig. 4a, CHM-1 promoted
the levels of cytosolic cytochrome c and AIF but decreased
the expression of pro-caspase-9 and pro-caspase-3. In
Fig. 4b, 750 nM of CHM-1 decreased the protein expres-
sion of Bcl-2, Bcl-xL and increased the protein expression
of Bax and BAD. These results suggest that CHM-1 induced
apoptotic response is mediated by mitochondrial pathway.
Therefore, we investigated the CHM-1-treated CT-26 cells
for the caspase-9 and caspase-3 activities by caspase
activity assay. Both caspase-9 and caspase-3 activities
increased at 12 h after CHM-1 treatment (Fig. 4c, d),
whereas the activity of caspase-8 was not affected (data not
shown). Moreover, pre-incubation with caspase-9 inhibitor
(Z-LEHD-FMK) or caspase-3 inhibitor (Z-DEVD-FMK),
strongly reduced the CHM-1-induced caspase-9 and
caspase-3 activities and an increase in the percentage of
viable cells in CT-26 cells (Fig. 4e). This confirms that
CHM-1-induced apoptosis is mediated by induction of
caspase-9 and -3 activities.
Anti-colorectal cancer activity of CHM-1-P on CT-26
orthotopic model. CHM-1-P was quickly converted into its
active parent compound CHM-1 by in vivo pharmaco-
kinetic analysis. On the basis of the significant growth-
inhibitory effect of CHM1 in vitro, we tested the effects of
CHM-1-P on the survival time of CT-26 orthotopic model
(CT-26/BALB/c mice). We orally administered 10 and
30 mg/kg of CHM-1-P and i.p. administered 30 mg/kg of
5-FU in BALB/c mice after they had been inoculated with
CT-26 cells. As shown in Fig. 5a, 10 and 30 mg/kg of
CHM-1-P significantly prolonged the survival time of
CT-26/BALB/c colorectal cancer mice. The average life
span on CHM-1-P (10 mg/kg) was prolonged by 144.44%
and on CHM-1-P and 5-FU (30 mg/kg) was prolonged by
155.56%. CHM-1 showed a broad spectrum and high
degree of in vivo antitumor activity. In addition, we
observed no significant difference in body weight between
control and CHM-1-P-treated animals (Fig. 5b). The total
tumor volume on colon, spleen and liver tissues were
excised from individual animals after 35 days treatment.
The photograph and spleen weight were examined and
representative results are presented. Our data showed that
spleen enlargement (Fig. 5c), total tumor volume (Fig. 5d)
and liver metastasis (Fig. 5e) were significantly reduced in
the CHM-1-P and 5-FU treated mice in comparison to
those in CT-26/BALB/c mice. The results supported that
CHM-1-P and 5-FU in CT-26/BALB/c mice were due to
anti-colorectal cancer activity.
Discussion
Anti-mitotic agents interact in the tubulin/microtubule
system constitute an important concept in anti-cancer drug
Fig. 3 Effects of CHM-1 on cell cycle distribution, associated
proteins levels, and CDK1 kinase activity in CT-26 cells. Cells were
treated with 750 nM CHM-1 for 0, 12, 24 and 48 h. Cell cycle
distribution (a) were determined by flow cytometric assay as
described in ‘‘Materials and methods’’. Cells were treated with
750 nM CHM-1 for 0, 6, 12 and 24 h, then total proteins were
prepared then detected for CDK1, cyclin A, cyclin B by Western
blotting (b) and CDK1 kinase activity (c). CDK1 kinase activity was
measured as described in ‘‘Materials and methods’’. Data represents
mean ± SD of three experiments. *p \ 0.05
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discovery [8, 20]. Several microtubule-binding agents have
been developed as clinical anti-cancer agents such as Taxol
and Vinblastine [8, 20]. CHM-1 was developed in hopes of
reducing the side effects associated with other microtubule
inhibitors. Our data showed that 750 nM of CHM-1 sig-
nificantly inhibited the proliferation of CT-26 colorectal
adenocarcinoma cells. However, Teng et al. demonstrated
that CHM-1 was less toxic to normal cells, including
human fibroblasts (MRC5) and mouse hepatocytes [11,
12], but no report has addressed the effects of CHM-1 on
colorectal cancer. We firstly investigated CHM-1 and
CHM-1-P in CT-26 cells for anti-cancer activities with
associated molecular mechanisms in vitro and in vivo.
Our results indicated that CHM-1 induced cytotoxicity in
CT-26 cells in a dose- and time-dependent manner, acting
through G2/M arrest and apoptosis. We also demonstrated
that 10 mg/kg and 30 mg/kg of CHM-1-P in BALB/c mice
inoculated with CT-26 cells models were due to anti-
colorectal cancer activity. Teng et al. demonstrated that
CHM-1 induced a significant concentration-dependent
growth inhibition and induced apoptosis, then produced
dose-dependent tumor regression and prolonged the
Fig. 4 Effects of CHM-1 on the levels change of apoptosis associ-
ated proteins levels in CT-26 cells. Cells were treated with 750 nM
CHM-1 for 0, 6, 12 and 24 h, total or cytosolic proteins were detected
(a) the levels of cytochrome c, pro-caspase-9, pro-caspase-3 and AIF;
(b) the levels of Bax, BAD, Bcl-2 and Bcl-xL expressions by Western
blotting as described in ‘‘Materials and methods’’. Cells were treated
with 750 nM CHM-1 in the presence or absence 20 lM of caspase-9
and -3 inhibitors for various time periods then cells were collected for
caspase-3 (c) and caspase-9 (d) activities determination and cell
viability (e) according to the manufacturer’s instructions as described
in ‘‘Materials and methods’’. Data represents mean ± SD of three
experiments. *p \ 0.05, **p \ 0.01, ***p \ 0.001
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lifespan of mice carrying liver cancer xenografts, indicat-
ing its in vivo efficacy [11]. We suggest that CHM-1 rep-
resents a promising candidate as an anti-cancer agent with
low toxicity to normal cells.
Microtubule interacting agents may interfere with the
dissociation of chromosomes, thus inducing G2/M arrest
and/or apoptosis. The G2/M checkpoint plays an important
role in providing time for DNA repair, whereas apoptosis
may function to remove damaged cells. Our data showed
that CHM-1 started to induce G2/M phase arrest at 12–48 h
of treatment. The CDK1/Cyclin B complex is one of the
major regulators leading the G2 to M progression or
apoptosis [16]. Our results showed a decrease in the protein
level of CDK1, Cyclin A and Cyclin B, and a decrease in
the activity of CDK1 at 12 and 24 h after CHM-1 treat-
ment. These results are similar to previous reports
regarding the regulation of CDK1/cyclin activity [16]. It
was reported that anti-mitotic agents induced apoptosis
through decreased CDK1 kinase activity. We are now in
the progress of elucidating the possibility by directly
blocking CDK1 activity or blocking its down stream tar-
gets (such as Bad, Bcl-2 and survivin).
Activation of the caspase is the major mechanism that
promotes apoptosis in response to death-inducing signals
from cell surface receptors and mitochondria stress [21]. In
this study, we observed the induction of caspase-9 and
caspase-3 specific activities by CHM-1. We also found that
caspase-9 and caspase-3 inhibitors individually prevented
CHM-1-induced apoptosis in CT-26 cells. Many reports
have shown that during apoptosis, some pro-apoptotic
factors, including pro-caspase and caspase-independent
factors such as AIF, can be released from mitochondria into
Fig. 5 In vivo anti-tumor activity of CHM-1-P. CT-26/BALB/c mice
orally administered 10 and 30 mg/kg of CHM-1-P or i.p. administered
30 mg/kg of 5-FU. Each value represents the ratio of survival animal
(a), body weight (b), spleen weight (c), total tumor volume (d) and
liver (e) of CT-26/BALB/c mice with CHM-1 administrations
(n = 5). Body and spleen weight results were expressed as
mean ± SD and the difference between the groups were tested by
one way ANOVA. Significant differences between values for CT-26/
BALB/c mice and various treatment are shown ***p \ 0.001
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cytosol [22–24]. In Western blot analysis, our results
showed that AIF also involved in the CHM-1 induced
apoptosis. Teng et al. demonstrated that CHM-1 induced
AIF translocation and nuclear condensation in HA22T cells
[11]. We suggested that CHM-1-induced apoptosis in
CT-26 cells is mediated through the activation of caspase
cascades, AIF translocation and mitochondria-dependent
pathway. These differences in results between the two
studies may be study in different cells types and treatment
conditions.
Bcl-2 family members have been reported in the regula-
tion of mitochondria-mediated apoptotic pathways [25]. It is
also reported that Bcl-2 and Bax locate in the mitochondrial
outer-membrane and the Bcl-2/Bax ratio regulates the
release of mitochondrial cytochrome c to cytosol [25, 26].
Our results indicated that CHM-1 promoted pro-apoptotic
Bax, BAD levels and inhibited the levels of anti-apoptotic
Bcl-2, Bcl-xL, which lead to the changes of the ratio of Bax/
Bcl-2, which lead to the release of cytochrome c, pro-
caspase-9 and AIF from the mitochondrial to the cytosol.
After cytochrome c is released from the mitochondria, it
binds to Apaf-1 and ATP and then binds to pro-caspase to
form apoptosome, which activates caspase-3, leading to
apoptosis.
Concentrated and selected accumulation of anti-cancer
drugs at the tumor site is essential for the success of drug
treatment in vivo. Teng et al. have reported that CHM-1
injected i.p. inhibited tumor growth and prolonged the
lifespan in mice inoculated with HA22T cells [11]].
Furthermore, CHM-1-P can significantly improve the water
insolubility of CHM-1, prolong the circulation times in the
blood, and enhance anti-tumor efficacy. Our studies
showed that both 10 mg/kg and 30 mg/kg of CHM-1-P
significantly prolonged the survival time of CT-26/BALB/c
colorectal cancer mice. In addition, spleen enlargement,
colon tumors, and liver metastasis were significantly
reduced in CHM-1-P and 5-FU treated mice compared to
those of CT-26/BALB/c mice. The proposed signaling
pathways of CHM-1-induced G2/M arrest and apoptosis in
CT-26 colorectal adenocarcinoma cells are shown in
Fig. 6.
Conclusion
We demonstrated that CHM-1 and CHM-1-P exhibit novel
anti-colorectal adenocarcinoma agents, and they have the
potential to develop into a clinical trial candidate in the
future.
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